MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'gastric cancer'. Sat, 03 Sep 2011 02:36:14 +0100 http://www.medworm.com/index.php?rid=4670109&cid=t_96072_87_f&fid=39187&url=http%3A%2F%2Fgetbetterhealth.com%2Fdoes-your-doctor-trust-you%2F2011.04.02 Members of the  American public are frequently surveyed about their trust in various professionals.  Doctors and nurses usually wind up near the top of the list, especially when compared to lawyers, hairdressers and politicians.  Trust in professionals is important to us: they possess expertise we lack but need, to solve problems ranging from the serious (illness) to the relatively trivial (appearance). How much professionals trust us seems irrelevant: our reciprocity is expressed in the form of payment for services rendered or promised, our recommendations to friends and families and repeat appearances. So I was surprised to read an article in the Annals of Family Medicine describing a new scale to measure doctors’ trust in their patients.  This scale, based on input from focus grou... Better Health blogs http://www.medworm.com/rss/comments.php?id=4670109 Sat, 02 Apr 2011 18:00:08 +0100 4670109 http://www.medworm.com/index.php?rid=4197360&cid=t_96072_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FfSAWlxdOWBA%2F Hello, everyone. Yet another day is unfolding here on the Pharmalot corporate campus, where the sun is shining, the dogs are barking and the short people are hustling off to the local school house for a few hours before the holiday weekend begins. As for us, we are savoring a needed cup of stimulation and perusing the news of the world. As always, we ask you to join us and, of course, we wish you a pleasant day… Roche Ends Hep C Collaboration With Ligand Pharma (Reuters) Glaxo Closing Toothpaste Facilities In Australia (MSN) Amira Pharma Cuts Staff In Half (San Diego Union-Tribune) Testosterone Lotion Wins Approval (Bloomberg News) State Senator Tries To Find Buyer For Roche Plant (WMBF) Glaxo Exits US Penicillin Biz, Sells Plants To Dr. Reddy’s (Associated Press) UK’s NI... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4197360 Wed, 24 Nov 2010 12:20:53 +0100 4197360 http://www.medworm.com/index.php?rid=3787029&cid=t_96072_111_f&fid=39123&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2Fnursingcomments%2Ftdtc%2F%7E3%2FGa7_4BTRZ6Y%2F                 Stomach cancer (also called gastric cancer) is the growth of cancer cells in the lining and wall of the stomach.  These two terms most often refer to stomach cancer that begins in the mucus-producing cells on the inside Early Gastric Cancer lining of the stomach (adenocarcinoma).  Adenocarcinoma is the most common type of stomach cancer.  For information purposes, it might be helpful to know that the body is made up of many types of cells.  Normally, cells grow, divide and then die.  Sometimes, cells change and begin to grow and divide more quickly than normal cells.  Rather than dying, these abnormal cells clump together to form tumors.  If these tumors are malignant (cancerous), they can invade and kill your body’s healthy tissues.  From these... Nursing Comments blogs http://www.medworm.com/rss/comments.php?id=3787029 Sat, 24 Jul 2010 13:07:32 +0100 3787029 http://www.medworm.com/index.php?rid=3318684&cid=t_96072_155_f&fid=38412&url=http%3A%2F%2Fpathlabmed.typepad.com%2Fsurgical_pathology_and_la%2F2010%2F03%2Ftrastumuzab-approved-for-treatment-of-her2positive-.html from primeLines:"On December 17, 2009, Roche’s trastuzumab (Herceptin®) received a positive recommendation from the European Medicines Agency (EMEA) for use in combination with standard chemotherapy for the treatment of previously untreated patients with HER2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction. The positive opinion for this new indication was issued in record time due to high unmet medical need and data from the ToGA trial (my emphasis), which demonstrated an increase in overall survival (OS) for patients with advanced HER2-positive gastric cancer who received trastuzumab plus chemotherapy (intravenous fluorouracil or capecitabine and cisplatin) compared to chemotherapy alone."I have done the immunostain for HER2 routinely on the las... The Daily Sign-Out blogs http://www.medworm.com/rss/comments.php?id=3318684 Mon, 01 Mar 2010 18:20:20 +0100 3318684 http://www.medworm.com/index.php?rid=3189110&cid=t_96072_87_f&fid=34865&url=http%3A%2F%2Fwww.thecancerblog.com%2F2010%2F01%2F19%2Fmediterranean-diet-reduces-stomach-cancer-risk%2F Filed under: Diets, Cancer prevention foods, Gastric cancerMediterranean diet advocates have another reason to cheer for their favorite foods. Following the Mediterranean diet may reduce your stomach cancer risk, according to a new study from Spain. The diet, similar to the traditional Greece and Southern Italian diet, emphasizes fruits, vegetables, legumes, fish and cereals. It limits red meat consumption, allows small amounts of wine and uses olive oil as the main fat. Doctors have championed this diet for several years because it has been linked to reducing the risk of depression, inflammation, premature death, diabetes, birth defect, heart disease, Alzheimer's and obesity. According to the study published in the American Journal of Clinical Nutrition, adopting the diet lowers th... The Cancer Blog blogs http://www.medworm.com/rss/comments.php?id=3189110 Tue, 19 Jan 2010 00:00:00 +0100 3189110 http://www.medworm.com/index.php?rid=2872082&cid=t_96072_155_f&fid=38412&url=http%3A%2F%2Fpathlabmed.typepad.com%2Fsurgical_pathology_and_la%2F2009%2F10%2Fnovel-classification-for-gastric-cancer.html A multi-institutional study published online on Oct. 1 in PLoS Genetics examined 301 gastric carcinomas using gene expression profiles and a pathway prediction model to identify major oncogenic pathways involved in gastric cancer and relate expression of these pathways to patient survival.  They found proliferation/stem cell-related, Wnt/beta-catenin, and NF-kappaB pathways are deregulated in over 70% of the gastric cancers they studied.  Furthermore, the found patterns of pathway co-activation associated with survival.  This is a free access paper so please download and read.Reading the "Materials and Methods" of this paper is worthwhile in itself because the strategy the authors used is well-conceived and explained.  More importantly, this study demonstr... The Daily Sign-Out blogs http://www.medworm.com/rss/comments.php?id=2872082 Wed, 07 Oct 2009 03:13:40 +0100 2872082 http://www.medworm.com/index.php?rid=2474471&cid=t_96072_155_f&fid=38412&url=http%3A%2F%2Fpathlabmed.typepad.com%2Fsurgical_pathology_and_la%2F2009%2F06%2Fasco-2009herceptin-in-gastric-cancer.html As a follow-up to my previous post on HER2 in gastric cancer, here is a summary of the new results from the ToGA trial presented at ASCO 2009 which have been called "practice-changing."This multinational study was conducted in 594 patients with HER2-positive disease, of nearly 4000 patients with advanced gastric cancer, screened for HER2 expression by both FISH and IHC.  All patients received chemotherapy (mostly cisplatin and capecitabine) and half were randomized to receive trastuzumab.  This trial was stopped early, after 17 months, because of the benefit seen.The improvement in overall survival was 2.7 months, from 11.1 months in the chemotherapy group to 13.8 months in the trastuzumab group (hazard ratio, 0.74, P = .0046).  In addition, trastuzumab im... The Daily Sign-Out blogs http://www.medworm.com/rss/comments.php?id=2474471 Fri, 12 Jun 2009 13:51:00 +0100 2474471 http://www.medworm.com/index.php?rid=2442860&cid=t_96072_155_f&fid=38412&url=http%3A%2F%2Fpathlabmed.typepad.com%2Fsurgical_pathology_and_la%2F2009%2F05%2Fher2-in-gastric-cancer.html I was listening to a preview of the 2009 ASCO Conference (starting on May 29) on Medscape and one of the anticipated studies being presented is the results of the ToGA trial, a multi-center, international phase III trial evaluating the combination of trastuzumab with standard 5FU plus cisplatin chemotherapy in advanced HER2 positive gastric cancer.  Update to follow but meanwhile. . .There is a nice review of the subject in Annals of Oncology, 2008;19:1523-1529 by Gravalos and Jimeno.  Preliminary data from this trial reported at ASCO 2007 in an abstract the HER2-positive rate in gastric cancer is about 24% (about what it is in breast cancer) and similar concordance between IHC and FISH (87%) but that there is a marked difference in HER2 expression by histologic type (36% intes... The Daily Sign-Out blogs http://www.medworm.com/rss/comments.php?id=2442860 Thu, 28 May 2009 20:28:46 +0100 2442860 http://www.medworm.com/index.php?rid=704446&cid=t_96072_87_f&fid=34865&url=http%3A%2F%2Fwww.thecancerblog.com%2F2007%2F06%2F29%2Fnccn-updates-guidelines-for-treatment-of-esophageal-and-gastric%2F Filed under: Chemotherapy, Esophageal Cancer, Stomach Cancer, Radiation, Gastric cancer, SurgeryIn late May, the National Comprehensive Cancer Network (NCCN) announced updates to two NCCN Clinical Practice Guidelines in Oncology(TM) -- Esophageal Cancer and Gastric Cancer. The panel added oral fluoropyrimidine, Capecitabine (Xeloda(R), Roche) as an option for treatment of esophageal and gastric cancer due to favorable Phase III trials. The panel also states that capecitabine may replace 5-FU and oxaliplatin may replace cisplatin in triplet regimens for advanced esophageal and gastric cancer. Additional updates and the NCCN Clinical Practice Guidelines in Oncology(TM) are available at www.nccn.org free of charge.Read | Permalink | Email this | Linking Blog... The Cancer Blog blogs http://www.medworm.com/rss/comments.php?id=704446 Fri, 29 Jun 2007 04:00:00 +0100 704446